<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03882892</url>
  </required_header>
  <id_info>
    <org_study_id>P02154</org_study_id>
    <secondary_id>MK-0653-017</secondary_id>
    <secondary_id>P02154</secondary_id>
    <nct_id>NCT03882892</nct_id>
  </id_info>
  <brief_title>Long-Term Safety and Tolerability of Ezetimibe (SCH 58235, MK-0653) With Atovastatin (P02154, MK-0653-017)</brief_title>
  <official_title>Long-Term, Safety and Tolerability Study of SCH 58235 or Placebo in Addition to Atorvastatin in Subjects With Primary Hypercholesterolemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to examine the long-term safety and tolerability of ezetimibe
      (SCH 58235) 10 mg once daily or placebo in combination with atorvastatin (10 to 80 mg/day)
      for up to 12 consecutive months in participants with primary hypercholesterolemia.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is a long-term extension study of the protocol P00692 parent study.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 2, 2001</start_date>
  <completion_date type="Actual">August 8, 2002</completion_date>
  <primary_completion_date type="Actual">August 8, 2002</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants Experiencing â‰¥1 Adverse Event (AE)</measure>
    <time_frame>Up to 12 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants Discontinuing from Study Treatment due to an Adverse Event (AE)</measure>
    <time_frame>Up to 12 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mean Percent Change from Baseline in Low-Density Lipoprotein Cholesterol (LDL-C)</measure>
    <time_frame>Baseline and 1.5, 3, 6, 9, and 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Percent Change from Baseline in High-Density Lipoprotein Cholesterol (HDL-C)</measure>
    <time_frame>Baseline and 1.5, 3, 6, 9, and 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Percent Change from Baseline in Triglyceride Levels</measure>
    <time_frame>Baseline and 1.5, 3, 6, 9, and 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Percent Change from Baseline in Total Cholesterol (TC)</measure>
    <time_frame>Baseline and 1.5, 3, 6, 9, and 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Percent Change from Baseline in Calculated Low-Density Lipoprotein Cholesterol (LDL-C)</measure>
    <time_frame>Baseline and 1.5, 3, 6, 9, and 12 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">400</enrollment>
  <condition>Hypercholesterolemia</condition>
  <arm_group>
    <arm_group_label>Placebo + Atorvastatin</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants who received placebo in the parent study (P00692) receive placebo (blinded) + atorvastatin (10 mg/day; open-label) in this study.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ezetimibe + Atorvastatin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants who received ezetimibe + atorvastatin, or atorvastatin alone, in the parent study (P00692) receive ezetimibe (blinded) + atorvastatin (10 mg/day; open-label) in this study.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ezetimibe</intervention_name>
    <description>Ezetimibe 10 mg tablets</description>
    <arm_group_label>Ezetimibe + Atorvastatin</arm_group_label>
    <other_name>SCH 58235</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Atovastatin</intervention_name>
    <description>Atorvastatin 10, 20, and 40 mg tablets at a daily dose of 10 to 80 mg</description>
    <arm_group_label>Ezetimibe + Atorvastatin</arm_group_label>
    <arm_group_label>Placebo + Atorvastatin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo tablets matched to ezetimibe</description>
    <arm_group_label>Placebo + Atorvastatin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Has successfully completed the 12-week double-blind, efficacy and safety parent study
             (P00692).

          -  If female, has a negative pregnancy test prior to study entry and, if of childbearing
             potential, agrees to practice an effective barrier method of birth control for the
             duration of the study and for 30 days after the last statin dose.

          -  If postmenopausal female receiving hormone therapy, a stable estrogen (ERT),
             estrogen/progestin (HRT) or raloxifene regimen must be maintained during the study
             period.

          -  Is willing to continue to follow their prescribed National Cholesterol Education
             Program (NCEP) Step 1 diet for the duration of the study.

        Exclusion Criteria:

          -  Has discontinued from the parent study (P00692) prior to study completion.

          -  Is in a situation, or has any condition which, in the opinion of the investigator may
             interfere with optimal participation.

          -  Is a pregnant or lactating female.

          -  Is human immunodeficiency virus (HIV) positive.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>86 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Merck Sharp &amp; Dohme Corp.</affiliation>
  </overall_official>
  <results_reference>
    <citation>Ballantyne CM, Lipka LJ, Sager PT, Strony J, Alizadeh J, Suresh R, Veltri EP. Long-term safety and tolerability profile of ezetimibe and atorvastatin coadministration therapy in patients with primary hypercholesterolaemia. Int J Clin Pract. 2004 Jul;58(7):653-8.</citation>
    <PMID>15311720</PMID>
  </results_reference>
  <verification_date>June 2019</verification_date>
  <study_first_submitted>March 19, 2019</study_first_submitted>
  <study_first_submitted_qc>March 19, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">March 20, 2019</study_first_posted>
  <last_update_submitted>June 11, 2019</last_update_submitted>
  <last_update_submitted_qc>June 11, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">June 13, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypercholesterolemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ezetimibe</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf</ipd_description>
    <ipd_url>http://engagezone.msd.com/ds_documentation.php</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

